0.18
0.18 (0%)
As of Feb 14, 2025
Hepion Pharmaceuticals, Inc. [HEPA]
Source:
Company Overview
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Morristown, New Jersey, previously focused on the development of drug therapy for treatmentof chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
| Country | United States |
| Headquarters | edison, new jersey |
| Phone Number | 732-902-4000 |
| Industry | manufacturing |
| CEO | John Cavan |
| Website | Hepion.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-19.3 |
| Net Income | $-13.2 |
| Net Cash | $-14.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -133.9% |
| Profit as % of Stockholder Equity | 708% |
Management Effectiveness
| Return on Equity | 708% |
| Return on Assets | -817.5% |
| Turnover Ratio | |
| EBITA | $-19.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1.6 |
| Total Liabilities | $3.5 |
| Operating Cash Flow | $-18.2 |
| Investing Cash Flow | $-0.6 |
| Financing Cash Flow | $4.3 |
